Genelux (GNLX) Share-based Compensation (2022 - 2026)
Genelux's (GNLX) quarterly Share-based Compensation came in at $1.4 million in Q1 2026, down 2.04% year-on-year from $1.4 million in Q1 2025, and down 9.19% quarter-over-quarter from $1.5 million in Q4 2025.
Genelux (GNLX) Share-based Compensation (2022 - 2026) Analysis & Trends
Genelux's Share-based Compensation history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 2.04% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 1.08% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, up 2.32% from the prior year.
- Share-based Compensation eased to $1.4 million in Q1 2026 per GNLX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $21.4 million in Q3 2023 and bottomed at -$42000.0 in Q4 2023.
- The 5-year median for Share-based Compensation is $1.4 million (2026), against an average of $2.4 million.
- Across the five-year window, Share-based Compensation tumbled 197.67% in 2023 and surged 3504.76% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $43000.0 in 2022, then tumbled by 197.67% to -$42000.0 in 2023, then jumped by 3504.76% to $1.4 million in 2024, then advanced by 7.34% to $1.5 million in 2025, then declined by 9.19% to $1.4 million in 2026.
- Per Business Quant, the three latest GNLX Share-based Compensation figures stand at $1.4 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | - |
| 10 | Genelux | 128.92 Mn | 128.92 Mn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |